Interleukin‐23: as a drug target for autoimmune inflammatory diseases
説明
<jats:title>Summary</jats:title><jats:p>Interleukin‐23 (IL‐23) is a member of the IL‐12 family of cytokines with pro‐inflammatory properties. Its ability to potently enhance the expansion of T helper type 17 (Th17) cells indicates the responsibility for many of the inflammatory autoimmune responses. Emerging data demonstrate that IL‐23 is a key participant in central regulation of the cellular mechanisms involved in inflammation. Both IL‐23 and IL‐17 form a new axis through Th17 cells, which has evolved in response to human diseases associated with immunoactivation and immunopathogeny, including bacterial or viral infections and chronic inflammation. Targeting of IL‐23 or the IL‐23 receptor or IL‐23 axis is a potential therapeutic approach for autoimmune diseases including psoriasis, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis. The current review focuses on the immunobiology of IL‐23 and summarizes the most recent findings on the role of IL‐23 in the pre‐clinical and ongoing clinical studies.</jats:p>
収録刊行物
-
- Immunology
-
Immunology 135 (2), 112-124, 2012-01-11
Wiley
